BUSINESSSTAT NEWS
STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials
GSK CEO Luke Miels announced a three-year cost-cutting plan targeting 1.9 billion pounds in annual savings by 2029, with funds reinvested into late-stage drug trials. The company aims to increase Phase 3 trials from 10 to 20 this year, focusing on areas like oncology, liver disease, vaccines, and HIV.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn
- STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
- GSK is acquiring lung cancer biotech Nuvalent in its biggest deal in over a decade
- GSK reports promising early results in ovarian and womb cancer drug trial